Brokerages Set Bausch + Lomb Corporation (NYSE:BLCO) Target Price at $17.42

Shares of Bausch + Lomb Corporation (NYSE:BLCO) have earned an average rating of “Hold” from the fifteen analysts that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $17.4167.

Several research firms have recently weighed in on BLCO. Wells Fargo & Company increased their price objective on Bausch + Lomb from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Friday, November 14th. JPMorgan Chase & Co. increased their price objective on shares of Bausch + Lomb from $13.00 to $16.00 and gave the company a “neutral” rating in a research report on Thursday, October 30th. Royal Bank Of Canada boosted their target price on shares of Bausch + Lomb from $19.00 to $21.00 and gave the company an “outperform” rating in a research report on Tuesday, January 27th. Citigroup raised shares of Bausch + Lomb from a “neutral” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Thursday, December 11th. Finally, Wall Street Zen upgraded shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st.

Bausch + Lomb Stock Up 1.9%

Shares of Bausch + Lomb stock opened at $17.04 on Monday. The business has a fifty day simple moving average of $16.99 and a 200 day simple moving average of $15.74. Bausch + Lomb has a 12 month low of $10.45 and a 12 month high of $17.86. The stock has a market cap of $6.04 billion, a PE ratio of -19.59, a price-to-earnings-growth ratio of 0.99 and a beta of 0.61. The company has a quick ratio of 0.98, a current ratio of 1.51 and a debt-to-equity ratio of 0.76.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. boosted its position in Bausch + Lomb by 729.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after acquiring an additional 2,042 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Bausch + Lomb by 104.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after purchasing an additional 1,136 shares in the last quarter. Blue Trust Inc. grew its stake in Bausch + Lomb by 58.5% during the second quarter. Blue Trust Inc. now owns 4,502 shares of the company’s stock worth $59,000 after purchasing an additional 1,662 shares during the period. FNY Investment Advisers LLC increased its holdings in Bausch + Lomb by 93.8% in the second quarter. FNY Investment Advisers LLC now owns 6,200 shares of the company’s stock worth $80,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in Bausch + Lomb by 31.2% in the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after buying an additional 1,403 shares during the period. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.